Gerard Henry, MD
Urology · Bossier City, LANPI 1508862905
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 54 manufacturers reported payments, led by Boston Scientific at 56.9% of the total. Reporting peaked in 2019 at $98,515 and has fallen 75.2% since, to $24,447 in 2025. Among urology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,050 payments — averaging $243.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$146K
- Coloplast$65K
- EDAP Technomed Inc$23K
- Pfizer$8K
- Axonics, Inc.$3K
- Innovation Technologies Inc$2K
- plus $9K from 48 others
Across 84 payments — averaging $3376.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$98K
- Bluewind Medical$71K
- Pfizer$56K
- Coloplast$50K
- Axonics, Inc.$9K
What the payments were for
- Consulting fees$53,86021%
- Speaking & faculty fees$121,35547%
- Travel & lodging$35,36914%
- Food & beverage$24,65410%
- Education$20,5108%
- Entertainment$1560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMS$107,596
- TITAN$52,420
- FOCAL ONE$21,040
- ADVANCE$14,799
- AMS 700 CXR RTE KIT$13,280
- GENERAL - THERAPIES$6,188
- ORGOVYX$4,345
- XTANDI$2,590
- Bulkamid$2,126
- Axonics$1,993
- Irrisept$1,952
- GENERAL ERECTILE DYSFUNCTION$571
- INLYTA$370
- INTERSTIM$333
- Porges Coloplast$250
- ADVANTAGE FIT$159
- JELMYTO$156
- Tulsa-Pro$143
- PENILE & TESTICULAR RECONSTRUCTN$115
- Dormia$114
How this compares
$255,904 in reported general payments places this provider in the 95th percentile of 199 urology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 92 | $73,650 |
| MyrbetriqMirabegron | 85 | $51,625 |
| Mirabegron ErMirabegron | 28 | $10,444 |
| Testosterone Cypionate | 131 | $7,250 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 204 | $5,134 |
| Tolterodine Tartrate ErTolterodine Tartrate | 49 | $4,175 |
| Finasteride | 202 | $3,589 |
| Testosterone | 23 | $3,397 |
| Tamsulosin Hcl | 126 | $1,832 |
| Cabergoline | 29 | $1,298 |
| Trimethoprim | 22 | $1,126 |
| Dutasteride | 20 | $895 |
| Levofloxacin | 166 | $544 |
| Oxybutynin Chloride | 22 | $540 |
| Doxycycline Hyclate | 47 | $406 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $304 | $73,65092 claims |
| Astellas Pharma US IncMyrbetriq | $966 | $51,62585 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 199 urology providers in Louisiana.
Other urology in Bossier City
- William BundrickBossier City$8K
- Richard VanlangendonckNew Orleans$289K
- Ralph HendersonShreveport$211K
- Wayne HellstromNew Orleans$183K
- Colin GoudelockeNew Orleans$124K
- Sunil PurohitCovington$99K
- Raju ThomasNew Orleans$67K
- Louis KraneNew Orleans$62K
- Kevin HebertShreveport$54K
- Jorge CasoNew Orleans$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.